Cue Biopharma to Host Investor Call
07 juin 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
05 juin 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
25 mai 2023 17h00 HE
|
Cue Biopharma, Inc.
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three...
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
15 mai 2023 08h00 HE
|
Cue Biopharma, Inc.
Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma,...
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
09 mai 2023 16h35 HE
|
Cue Biopharma, Inc.
BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
08 mai 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
25 avr. 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
12 avr. 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
21 mars 2023 16h10 HE
|
Cue Biopharma, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose...
Cue Biopharma to Host Business Update Call and Webcast
15 mars 2023 08h00 HE
|
Cue Biopharma, Inc.
BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...